HekaBio
HekaBio is a Tokyo-based asset-light biopharma and MedTech platform that in-licenses early, de-risked healthcare innovations from overseas and commercializes them in Japan and APAC. It serves Japanese patients with cancer, autoimmune, CNS, and ophthalmic diseases, and overseas innovators seeking Japan/APAC market access.
- Company typePrivate
- Founded2016
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingServices
What HekaBio does
HekaBio K.K. is a privately held Tokyo-based healthcare platform founded in 2016 that operates an asset-light in-licensing, development, and commercialization model for world-leading biopharma and MedTech assets in Japan and the broader APAC region. The company addresses the well-documented drug and device lag between Japan and Western markets by acquiring rights to de-risked, early-stage assets from overseas innovators and shepherding them through PMDA regulatory pathways, clinical trials, reimbursement negotiations, and commercial launch. HekaBio's portfolio spans approximately 50 programs across oncology, autoimmune and inflammatory diseases, CNS and neurodegenerative disorders, ophthalmology, and regenerative medicine, with its flagship Alpha DaRT alpha-particle radiation therapy system having received Shonin marketing approval from Japan's Ministry of Health, Labour and Welfare in February 2025 for unresectable locally advanced or recurrent head and neck cancer, marking the first regulatory approval for the platform outside Israel.
The company's revenue model is based on licensing milestones and royalties from commercialization of in-licensed products, supplemented by strategic investments from corporate partners. HekaBio holds Japanese regulatory permits for Class I medical device manufacturing/sales and highly managed medical device sales/rental, enabling it to directly commercialize approved products. Its go-to-market relies on channel partnerships, most notably with Alfresa Holdings (Japan's largest pharmaceutical wholesaler at 2.9 trillion yen consolidated sales) for nationwide distribution, and direct relationships with leading clinical centers including the National Cancer Center Hospital, Tohoku University Hospital, and the Institute of Science Tokyo for trial execution and clinical adoption. Core products include the Alpha DaRT System (intratumoral radium-224 alpha-particle therapy), Precision-GI endoscopic biopsy device (from Limaca Medical), BetaCurve ophthalmic radiation therapy (from SalutarisMD), troculeucel NK cell therapy (from NKGen Biotech), SP163M neuropathy peptide (from Serpin Pharma), and the K-EXP biomarker platform (from KIFFIK Biomedical).
HekaBio is led by co-founders Rob Claar (CEO) and Ben Pratt (COO), who leverage prior experience from Junicon K.K. (healthcare market research) and Vorpal Technologies K.K. (pharmaceutical and medical device CRO). The advisory and board bench includes former Japan presidents of AbbVie, Merck KGaA, and Pfizer, former Salesforce/Yext CFO Steven Cakebread, and international M&A attorney Stephen Chelberg of Squire Patton Boggs. The company is currently transitioning from a development-stage platform to commercial-stage operations following Alpha DaRT approval.
HekaBio firmographics
Firmographics- Name
- HekaBio
- Legal name
- HekaBio K.K.
- Website
- https://heka.bio
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HekaBio is a Tokyo-based asset-light biopharma and MedTech platform that in-licenses early, de-risked healthcare innovations from overseas and commercializes them in Japan and APAC. It serves Japanese patients with cancer, autoimmune, CNS, and ophthalmic diseases, and overseas innovators seeking Japan/APAC market access.
- Ownership category
- akta.pro rank
HekaBio industry classification
Industry- Product category
- Biopharmaceutical and MedTech Licensing & Commercialization
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
Keywords
Where HekaBio is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
HekaBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- Licensing and Commercialization: HekaBio generates revenue through licensing agreements with overseas biotech/MedTech companies for Japanese market rights. They earn milestone payments during development phases and royalties upon commercialization. They also receive strategic investments from partners.
- Strategic Investments: The company raises capital through private funding rounds from corporate investors and financial partners to fund portfolio expansion and operations.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
HekaBio product offering
Product offeringCore offering
HekaBio K.K. is a biopharma and MedTech in-licensing and commercialization platform that brings world-leading healthcare innovations to Japan and the Asia-Pacific region. The company identifies, de-risks, clinically develops, secures regulatory approval (PMDA), and commercially launches overseas assets across oncology (including the approved Alpha DaRT alpha-radiation therapy), ophthalmology (BetaCurve), regenerative medicine (troculeucel NK cell therapy), and diagnostics (Precision-GI biopsy device), with revenue generated primarily through licensing milestones and royalties from partners such as Alpha Tau Medical, Limaca Medical, SalutarisMD, NKGen Biotech, and Serpin Pharma.
Product overview
HekaBio is an asset-light emerging commercial-stage biopharma and MedTech platform that in-licenses, develops, and commercializes world-leading healthcare innovations in Japan and the Asia-Pacific region. The company operates as a portfolio of partnered products rather than a single unified product. Its core offerings include the Alpha DaRT System (alpha-particle radiation cancer therapy) as its primary commercial product, supplemented by partnership-based products including Precision-GI (endoscopic biopsy device), K-EXP Platform (interstitial fluid diagnostics), BetaCurve (ophthalmic radiation therapy), troculeucel (NK cell therapy), SP163M (neuropathy treatment), and the Terrapeutics drug discovery platform. HekaBio focuses on oncology, CNS/neurodegenerative diseases, and autoimmune/inflammatory disorders, providing clinical development, regulatory navigation, and commercialization support through its network of pharma, MedTech, and hospital partners.
Differentiator
Problem solved
Functional benefit
Products and services
- Alpha DaRT System Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an alpha-particle cancer treatment that delivers intratumoral radium-224 sources to destroy solid tumors while sparing healthy tissue. HekaBio's primary commercial product, licensed from Alpha Tau Medical, received Shonin marketing approval in Japan for unresectable locally advanced or recurrent head and neck cancer.
- Precision-GI Endoscopic Biopsy Device Precision-GI is an automated motorized endoscopic ultrasound (EUS) biopsy device developed by Limaca Medical for improved tissue sampling in gastrointestinal cancer diagnosis, particularly pancreatic cancer. HekaBio holds Japanese commercialization rights and is preparing the device for the Japan market following its FDA 510(k) clearance.
- BetaCurve BetaCurve is an ophthalmic device developed by SalutarisMD that incorporates Strontium-90 for controlled delivery of episcleral radiation to treat Polypoidal Choroidal Vasculopathy (PCV), a subset of neovascular Age-related Macular Degeneration with high prevalence in Asia. HekaBio holds Japan commercialization rights.
- troculeucel (Autologous NK Cell Therapy) Troculeucel is an autologous NK cell therapy developed by NKGen Biotech intended for treating neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. HekaBio is partnering to bring troculeucel to Japan under Japan's regenerative medicine regulatory framework.
- K-EXP Interstitial Fluid Molecular Measurement Platform The K-EXP platform, developed by KIFFIK Biomedical, performs interstitial fluid (ISF) molecular measurement enabling biomarker detection across oncology, cardiology, neurology, and dermatology. HekaBio is leading the platform's expansion across Japan and the Asia-Pacific region.
- SP163M Peptide Drug SP163M is a peptide drug developed by Serpin Pharma for prevention of chemotherapy-induced peripheral neuropathy (CIPN). It protects nerves from neurotoxic chemotherapy drugs, facilitates nerve repair, and alleviates pain. HekaBio holds the commercialization lead in Japan, Korea, Taiwan, Australia, ASEAN, the Middle East, and North Africa.
Quantifiable outcome
- Portfolio of nearly 50 programs under management
- +1 more outcomes
Companies that use HekaBio
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
HekaBio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
HekaBio partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- KIFFIK BiomedicalcoreStrategic alliance to expand K-EXP interstitial fluid (ISF) molecular measurement platform across Japan and APAC. HekaBio will support regulatory strategy in Japan, serve as local strategic advisor, and assist in establishing clinical and commercial partnerships in Japan and Korea. Platform enables biomarker detection across oncology, cardiology, neurology, and dermatology.
- Alpha Tau Medical Ltd.coreLong-standing partnership to develop and commercialize Alpha DaRT (Diffusing Alpha Radiation Therapy) for solid tumors in Japan. Alpha Tau developed the technology and obtained Japanese regulatory approval (Shonin) through HekaBio's support. HekaBio preparing commercial launch and post-marketing surveillance. Japan is first country outside Israel to approve this innovative alpha-particle cancer therapy.
- TOWER Capital GroupminorStrategic partnership to expand generational health access in Japan. Partnership focuses on delivering innovative healthcare solutions across generations through global investment platform capabilities.
- Indonesia Inovasi SehatminorStrategic agreement to promote advanced medical technology adoption in Indonesia. Partnership aims to improve patient outcomes by delivering innovative solutions to healthcare providers, reflecting shared mission across borders.
- NKGen BiotechcoreStrategic partnership to bring novel autologous NK cell therapy (troculeucel) to Japan for neurodegenerative diseases including Alzheimer's and Parkinson's. Partnership aims to accelerate regulatory, manufacturing, and commercialization processes under Japan's regenerative medicine regulations.
- Alfresa Holdings CorporationcoreStrategic commercialization partnership with Japan's #1 pharmaceutical wholesale company (2.9 trillion yen consolidated sales). Alfresa will support distribution and commercialization of innovative pharmaceutical products. HekaBio also received capital investment from Alfresa as part of this partnership to accelerate market entry.
- Serpin PharmaminorPartnership for SP163M peptide drug development to prevent chemotherapy-induced peripheral neuropathy (CIPN). HekaBio will lead commercialization in Japan, Korea, Taiwan, Australia, ASEAN, Middle East, and North Africa. Includes strategic investment in Serpin Pharma.
- Terrapeutics Pharma Ltd.minorPartnership to introduce Terrapeutics' innovative drug discovery platform leveraging soil bacteria-derived molecules to Japanese pharma. HekaBio CEO Rob Claar joins Terrapeutics' Advisory Board. Platform enables rapid identification of natural inhibitors for challenging drug targets.
- Limaca Medical Ltd.corePartnership for Precision-GI endoscopic biopsy device for Japanese market. HekaBio supporting regulatory approval from PMDA, sales preparation, physician training, and domestic logistics. Device received FDA 510(k) clearance and CMS TPT payment approval in US, with HekaBio pursuing Japanese commercialization.
- SalutarisMDcoreLicensing and commercialization agreement for BetaCurve device - Sr90 beta radiation delivery system for Polypoidal Choroidal Vasculopathy (PCV) treatment, a subset of wet age-related macular degeneration prevalent in Asia. Second major radiotherapy program after Alpha DaRT.
- Cosmo Public Relations CorporationminorStrategic partnership and investment from Cosmo Healthcare to increase awareness and accessibility of bioscience innovations. Cosmo brings established network in Japanese healthcare communications and media.
- Orgenesis Inc.coreLicense and joint venture agreement for clinical development and commercialization of regenerative and cell/gene therapy products in Japan. Focus on diabetes and autoimmune diseases. Part of HekaBio's strategy to bring cell therapies to Japanese market leveraging favorable regulatory environment.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
HekaBio competitors and assessment
Company assessmentBroad incumbents
- Syneos Health: Global biopharma services organization providing CRO and commercialization services across clinical development and commercial launch. Comparable business model to HekaBio's clinical execution and commercialization functions but at global scale and without HekaBio's Japan-only regulatory focus.
- Daiichi Sankyo: Leading Japanese pharma company with strong oncology pipeline and global commercialization capabilities. Relevant as a benchmark Japanese pharma incumbent and as a representative acquirer/strategic-partner profile for in-licensing platforms like HekaBio.
- Suzuken: One of Japan's top pharmaceutical wholesale groups with national distribution infrastructure. Comparable to Alfresa and Medipal as a potential channel partner; relevant as a benchmark for Japanese pharma distribution economics that ultimately govern HekaBio's launch royalty potential.
- MEDIPAL Holdings: Japan's second-largest pharmaceutical wholesaler (after Alfresa), distributing pharma products and medical devices nationwide. Comparable to Alfresa (HekaBio's distribution partner) — relevant as adjacent channel partner and as a potential competing commercialization route for Japanese market access.
- Astellas Pharma: Major Japanese-headquartered global pharma company with significant oncology and specialty therapeutics franchises. Comparable as a Japanese pharma incumbent that competes for licensed assets and that any large pharma acquirer of HekaBio would likely resemble.
Others
- Alfresa Holdings: Japan's #1 pharmaceutical wholesaler (¥2.9T consolidated sales) and HekaBio's strategic commercialization partner since June 2025. Included as an adjacent ecosystem participant — also a strategic investor — rather than a direct competitor since the relationship is partnership-based.
Direct peers
- Sosei Group: Tokyo-listed biopharma company that in-licenses and develops therapeutic candidates for Japan and global markets, including the Heptares GPCR platform. Highly comparable in-licensing and development model focused on Japan-rooted commercialization, though Sosei has more proprietary IP and is publicly traded at meaningful scale.
- EPS Holdings: Japanese CRO and healthcare services group supporting drug development, clinical trials, and post-marketing surveillance across Asia. Operates a similar asset-light services model in Japan and offers SMO/CRO/sales-promotion capabilities comparable to HekaBio's clinical execution and commercialization functions.
- CMIC Group: Tokyo-headquartered pharma services company providing CRO, CDMO, SMO, and consulting services across Japan and APAC. Closely comparable to HekaBio's Japan-focused biopharma development and commercialization platform model, though CMIC is significantly larger and more diversified across service lines.
- InvoX Pharma: UK- and Asia-focused in-licensing and development platform (subsidiary of Sino Biopharmaceutical) that acquires and develops late-stage pharma assets. Similar asset-light in-licensing model with focus on bridging Western/Asian assets, though InvoX is better capitalized and operates at later asset stages.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
HekaBio social profiles
Digital presenceHekaBio compliance and trust
Trust signalCompliance3 records
HekaBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
HekaBio leadership team
Management profileNumber of profiles
Profiles9 records
HekaBio subsidiaries and ownership
Company hierarchySubsidiaries1 record
HekaBio funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HekaBio M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HekaBio
What does HekaBio do?
HekaBio K.K. is a biopharma and MedTech in-licensing and commercialization platform that brings world-leading healthcare innovations to Japan and the Asia-Pacific region. The company identifies, de-risks, clinically develops, secures regulatory approval (PMDA), and commercially launches overseas assets across oncology (including the approved Alpha DaRT alpha-radiation therapy), ophthalmology (BetaCurve), regenerative medicine (troculeucel NK cell therapy), and diagnostics (Precision-GI biopsy device), with revenue generated primarily through licensing milestones and royalties from partners such as Alpha Tau Medical, Limaca Medical, SalutarisMD, NKGen Biotech, and Serpin Pharma.
Is HekaBio a public or private company?
HekaBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was HekaBio founded?
HekaBio was founded in 2016. It employs 11 to 50 people.
Where is HekaBio based?
HekaBio is headquartered in Tokyo, Japan, in the Asia region.
How does HekaBio make money?
Two revenue lines are on record. Licensing and Commercialization is the primary driver. The others are strategic Investments.
Who are HekaBio's main competitors?
Broad incumbents on record are Syneos Health, Daiichi Sankyo, Suzuken, MEDIPAL Holdings and Astellas Pharma. Alfresa Holdings is listed as an others. Direct peers are Sosei Group, EPS Holdings, CMIC Group and InvoX Pharma.
Does HekaBio have an API?
No public API is recorded for HekaBio.
What industry is HekaBio in?
HekaBio's product category is Biopharmaceutical and MedTech Licensing & Commercialization. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 3841.